Application of In Vivo Induced Antigen Technology (IVIAT) to Bacillus anthracis

Sean M. Rollins, Amanda Peppercorn, John S. Young et al. · 2008

Read Application of In Vivo Induced Antigen Technology (IVIAT) to Bacillus anthracis by Sean M. Rollins, Amanda Peppercorn, John S. Young et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001824.txt.

Introduction

Sean M. Rollins, Amanda Peppercorn, John S. Young, and their co-authors applied a screening technique to the anthrax bacterium in a 2008 PLOS ONE research article. In vivo induced antigen technology, or IVIAT, identifies bacterial antigens expressed during infection but not during standard lab culturing. It works by probing the bacterium with antibodies from infected hosts.

Applying IVIAT to Bacillus anthracis, the team identified PagA, a known protective antigen, plus seven members of a sugar-uptake family among the infection-specific antigens. The full text gives the screen and the antigen list. Antigens the germ only shows inside a host are prime vaccine and diagnostic targets, since lab-grown bacteria hide them.

Catalog record

CREATORSean M. Rollins, Amanda Peppercorn, John S. Young et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001824

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Application of In Vivo Induced Antigen Technology (IVIAT) to Bacillus anthracis Authors: Sean M. Rollins, Amanda Peppercorn, John S. Young, Melissa Drysdale, Andrea Baresch, Margaret V. Bikowski, David A. Ashford, Conrad P. Quinn, Martin Handfield, Jeffrey D. Hillman, C. Rick Lyons, Theresa M. Koehler, Stephen B. Calderwood, Edward T. Ryan Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0001824 ABSTRACT In vivo induced antigen technology (IVIAT) is an immuno-screening technique that identifies bacterial antigens expressed during infection and not during standard in vitro culturing conditions. We applied IVIAT to Bacillus anthracis and identified PagA, seven members of a N-acetylmuramoyl-L-alanine amidase autolysin family, three P60 family lipoproteins, two transporters, spore cortex lytic protein SleB, a penicillin binding protein, a putative prophage holin, respiratory nitrate reductase NarG, and three proteins of unknown function. Using quantitative real-time PCR comparing RNA isolated from in vitro cultured B. anthracis to RNA isolated from BALB/c mice infected with virulent Ames strain B. anthracis , we confirmed induced expression in vivo for a subset of B. anthracis genes identified by IVIAT, including L-alanine amidases BA3767, BA4073, and amiA (pXO2-42); the bacteriophage holin gene BA4074; and pagA (pXO1-110). The exogenous addition of two purified putative autolysins identified by IVIAT, N-acetylmuramoyl-L-alanine amidases BA0485 and BA2446, to vegetative B. anthracis cell suspensions induced a species-specific change in bacterial morphology and reduction in viable bacterial cells. Many of the proteins identified in our screen are predicted to affect peptidoglycan re-modeling, and our results support significant cell wall structural remodeling activity during B. anthracis infection. Identification of L-alanine amidases with B. anthracis specificity may suggest new potential therapeutic targets. INTRODUCTION In vivo induced antigen technology (IVIAT) is an immuno-screening technique designed to identify immunogenic bacterial genes expressed specifically during infection [1] – [4] . We hypothesized that applying IVIAT to Bacillus anthracis , the cause of anthrax, could lead to increased understanding of bacterial events during infection, improved diagnostic assays, and novel therapeutic targets. IVIAT utilizes convalescent sera from patients or animals infected with a pathogen of interest [1] – [4] . Convalescent sera are pooled from several individuals and adsorbed against the cognate pathogen grown under standard laboratory culture conditions. Extensive adsorptions are performed to remove antibodies that bind bacterial antigens expressed in vitro, while retaining antibodies that recognize bacterial antigens specifically expressed during in vivo growth. Adsorbed serum is then used to probe an Escherichia coli -based inducible protein expression library of the pathogen. IVIAT thus provides a screen to identify proteins that generate a humoral immune response, and are displayed specifically during infection. Thus far, IVIAT has been applied to several pathogenic bacteria including Vibrio cholerae, Vibrio vulnificus, E. coli O157:H7, Salmonella enterica serovar Typhi, Streptococcus pyogenes (Group A), and Mycobacterium tuberculosis , among others [2] , [3] , [5] – [9] . In these applications, IVIAT has identified pathogen genes expressed uniquely in vivo, including antigens previously established to be expressed in vivo, and newly recognized virulence factors [2] , [3] , [5] – [9] . Identification of up-regulated virulence genes by IVIAT has been confirmed in complementary studies, including gene microarray analysis, quantitative real time PCR (RT-PCR), signature tagged mutagenesis, and recombinase in vivo expressed technologies (RIVET), among others [9] – [11] . Certain in vitro conditions have been identified that induce expression of B. anthracis genes involved in pathogenesis during anthrax, including expression of toxins and capsule. For instance, growth of B. anthracis in Nutrient Broth Yeast extract medium (NBY) in the presence of 5–20% CO 2 and sodium bicarbonate at 37°C (selected to mimic the physiology of blood) is associated with increased expression of protective antigen (PA) and capsule compared to that observed during growth in standard laboratory media such as Brain Heart Infusion (BHI) in the presence of air (0.03% CO 2 ) at 37°C [12] . Although PA itself is non-toxic, PA binds specific host cell receptors and forms a pre-pore, which binds either edema factor (EF) or lethal factor (LF) to create edema toxin (ET) and lethal toxin (LT), respectively [13] . Anti-PA immune responses correlate with protection from anthrax, and PA is a primary immunogen in existing anthrax vaccines [14] . Full virulence of B. anthracis also correlates with presence of B. anthracis capsule, which is comprised of poly-D-glutamic acid. The presence of capsule impedes opsonophagocytosis and clearance of B. anthracis organisms from infected hosts [15] . Un-encapsulated strains of B. anthracis are markedly attenuated in both humans and animals, despite their ability to express fully functional LT and ET complexes. Beneath the capsule is a proteinaceous S-layer, composed of two paracrystalline proteins (extractable antigen 1 [EA1] and surface array protein [SAP]) that cover the bacterial cell surface [16] . Beneath the S-layer is a peptidoglycan layer comprising the cell wall. B. anthracis contains two large virulence plasmids: genes encoding toxin proteins PA ( pagA ), LF ( lef ), and EF ( cya ) are on the large virulence plasmid pXO1 (182 kb; 143 ORFs), while genes encoding proteins involved in encapsulation are on the large virulence plasmid, pXO2 (96 kb; 85 ORFs). Many B. anthracis genes on pXO1, pXO2, and the single large chromosome have not been characterized, and it is possible that additional factors induced during infection and not under typical in vitro culture conditions contribute to B. anthracis pathogenesis. Identification of such gene products could improve our understanding of host-pathogen interactions during anthrax, and could assist further development of appropriate therapeutic, diagnostic, or preventative measures for anthrax. To identify antigenic B. anthracis proteins displayed specifically during B. anthracis infection, we applied IVIAT using convalescent sera from partially immunized macaques surviving aerosol challenge with wild type B. anthracis Ames spores, quantified expression of identified genes in a mouse model of virulent B. anthracis Ames infection, and performed preliminary functional analysis on a subset of identified B. anthracis gene products. RESULTS AND DISCUSSION Using IVIAT, we immuno-screened an approximately 125,000 clone inducible B. anthracis expression library in E. coli BL21(DE3) (17,000 pXO1 clones, 7,500 pXO2 clones, and 100,000 chromosomal clones). We identified 60 immuno-reactive clones, representing 25 distinct B. anthracis genes or gene fragments. Of these, we constructed full length constructs and confirmed immuno-reactivity of ten ( Table 1 ). Significant immuno-reactivity of clones containing in-frame protein-coding fragments of BXB0048 and BA2125 and lacking gene fragments of other B. anthracis genes was detected (these protein coding regions are not similar to any alternative B. anthracis proteins); however, immuno-reactivity could not be confirmed in clones containing the complete ORFs of these gene fragments, possibly suggesting inefficient expression or display of full-length products in E. coli . Since a number of identified seroreactive ORF products were predicted to be cell wall active amidases or hydrolases, to evaluate whether immuno-reactivity was unique to a given IVIAT-identified ORF, we also evaluated immuno-reactivity of paralogs of IVIAT-identified genes BA4073 (a predicted amidase) and pXO2-08 (a possible hydrolase and our most frequently identified ORF-product), and identified eight additional gene products with immuno-reactivity ( Table 2 ). TABLE: B. anthracis gene products identified by IVIAT. Functional category ORF Gene product-description, function (reference) Predicted cellular location Gene encoded by # of clones identified by primary screening/# of independent clones identified by primary screening Comments Virulence pXO1-110 ( pagA ) Protective

Read the complete text